Biblio

Found 4 results
Sort by: Author Title Type [ Year (Desc)]
Filters: Author is Goodin, D S  [Clear All Filters]
2011
Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Kappos L, Bogumil T, et al. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler [Internet]. 2011. Available from: http://www.hubmed.org/display.cgi?uids=21952094
2010
Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry [Internet]. 2010. Available from: http://www.hubmed.org/display.cgi?uids=20562430
2009
Ebers GC, Reder AT, Traboulsee A, Li D, Langdon D, Goodin DS, Wolf C, Beckmann K, Konieczny A, Investigators of the 16-Year Long-Term Follow-Up Study, et al. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther [Internet]. 2009;31:1724-1736. Available from: http://www.hubmed.org/display.cgi?uids=19808131
2008
Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC, . Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology [Internet]. 2008;71:766-773. Available from: http://www.hubmed.org/display.cgi?uids=18765653